Latest Contracts News

Alliance Aviation Services reported an 11.3% revenue increase to $333 million and a 9.9% rise in net profit to $28.9 million for H1 FY2025, navigating challenges from industrial action and contract reductions.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

St George Mining has forged a strategic partnership with global EPC leader Xinhai, securing an A$8 million investment and a pathway to fast-track the Araxá niobium-REE project in Brazil.

AGL Energy reported a solid first half of FY25 with underlying EBITDA slightly down but maintained strong operational momentum, while narrowing its full-year earnings guidance and announcing key leadership changes.

AGL Energy’s half-year results reveal a 15.3% revenue increase to $7.13 billion, but statutory profit plunges 83.2% to $97 million, reflecting margin pressures and significant provisions. The company declares a lower fully franked interim dividend of 23 cents per share.

Vection Technologies has secured a three-year, AUD$575k partnership with global insurer Generali to deploy AI-driven extended reality solutions enhancing workplace safety and client engagement.

IMDEX reported a 10% revenue decline in 1H25 amid subdued global exploration activity but delivered a robust 28% increase in EBITDA, maintaining a strong 30% margin and positioning itself for growth.

IMDEX Limited reported resilient half-year results for FY2025, achieving half-on-half revenue growth and maintaining margins despite a challenging mining exploration environment. The company strengthened its balance sheet and declared an interim dividend, positioning itself for future growth.

IMDEX Limited reported a significant 84% increase in net profit for the half-year ended December 31, 2024, even as revenue declined by 10%. The company declared a steady interim dividend, underscoring confidence amid mixed financial signals.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Amotiv Limited reported a modest 2.3% revenue increase in the first half of FY25, underpinned by acquisitions and strategic initiatives despite organic revenue softness and margin pressures. The company anticipates a stronger second half driven by new business wins and pricing actions.

Amotiv Limited posted a modest 2.3% revenue increase for H1 FY25 despite a 35.8% plunge in net profit after tax, driven by impairments and restructuring. The company signals optimism for FY25 growth, underpinned by new product launches and disciplined cost management.